Dissemin is shutting down on January 1st, 2025

Published in

Nature Research, Nature Immunology, 6(25), p. 1073-1082, 2024

DOI: 10.1038/s41590-024-01833-w

Links

Tools

Export citation

Search in Google Scholar

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Journal article published in 2024 by Torben Schiffner, Ivy Phung ORCID, Rashmi Ray, Adriana Irimia, Ming Tian, Olivia Swanson ORCID, Jeong Hyun Lee, Chang-Chun D. Lee ORCID, Ester Marina-Zárate ORCID, So Yeon Cho, Jiachen Huang, Gabriel Ozorowski ORCID, Patrick D. Skog, Andreia M. Serra, Kimmo Rantalainen ORCID and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractA key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic diversity is the design of priming immunogens that induce rare bnAb-precursor B cells. The high neutralization breadth of the HIV bnAb 10E8 makes elicitation of 10E8-class bnAbs desirable; however, the recessed epitope within gp41 makes envelope trimers poor priming immunogens and requires that 10E8-class bnAbs possess a long heavy chain complementarity determining region 3 (HCDR3) with a specific binding motif. We developed germline-targeting epitope scaffolds with affinity for 10E8-class precursors and engineered nanoparticles for multivalent display. Scaffolds exhibited epitope structural mimicry and bound bnAb-precursor human naive B cells in ex vivo screens, protein nanoparticles induced bnAb-precursor responses in stringent mouse models and rhesus macaques, and mRNA-encoded nanoparticles triggered similar responses in mice. Thus, germline-targeting epitope scaffold nanoparticles can elicit rare bnAb-precursor B cells with predefined binding specificities and HCDR3 features.